Cantor Fitzgerald Decreases Earnings Estimates for Exagen

Exagen Inc. (NASDAQ:XGN) – Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Exagen in a research note issued to investors on Wednesday, March 12th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will post earnings of ($0.59) per share for the year, down from their prior forecast of ($0.41). Cantor Fitzgerald has a “Overweight” rating and a $8.00 price target on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share.

XGN has been the topic of several other research reports. William Blair reaffirmed an “outperform” rating on shares of Exagen in a research note on Wednesday. Canaccord Genuity Group lifted their target price on Exagen from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

Exagen Trading Up 6.3 %

NASDAQ:XGN opened at $3.56 on Friday. The business has a 50 day simple moving average of $3.78 and a 200 day simple moving average of $3.58. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The firm has a market capitalization of $62.79 million, a P/E ratio of -3.79 and a beta of 1.40. Exagen has a 12-month low of $1.30 and a 12-month high of $6.22.

Institutional Trading of Exagen

Hedge funds have recently added to or reduced their stakes in the business. Verus Capital Partners LLC bought a new stake in shares of Exagen in the 3rd quarter worth $39,000. Corient Private Wealth LLC bought a new stake in shares of Exagen in the 4th quarter worth $45,000. Virtu Financial LLC bought a new stake in shares of Exagen in the 4th quarter worth $46,000. Marshall Wace LLP bought a new stake in shares of Exagen in the 4th quarter worth $66,000. Finally, Northern Trust Corp raised its stake in shares of Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after buying an additional 2,630 shares in the last quarter. Institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).